Neoantigens are newly formed peptides created from somatic mutations that are capable of
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …

The accurate selection of neoantigens that bind to class I human leukocyte antigen (HLA)
and are recognized by autologous T cells is a crucial step in many cancer immunotherapy …

Background Tumor-specific mutations form novel immunogenic peptides called
neoantigens. Neoantigens can be used as a biomarker predicting patient response to …

T-cell recognition of somatic mutation-derived cancer neoepitopes can lead to tumor
regression. Due to the difficulty to identify effective neoepitopes, constructing a database for …

Background The use of next-generation sequencing technologies has enabled the rapid
identification of non-synonymous somatic mutations in cancer cells. Neoantigens are …

Neoantigens are tumor-specific peptide sequences resulting from sources such as somatic
DNA mutations. Upon loading onto major histocompatibility complex (MHC) molecules, they …

Background Next generation sequencing has yielded an unparalleled means of quickly
determining the molecular make-up of patient tumors. In conjunction with emerging, effective …

Neoantigens can function as actual antigens to facilitate tumor rejection, which play a crucial
role in cancer immunology and immunotherapy. Emerging evidence revealed that …

Neoantigens, which are expressed on tumor cells, are one of the main targets of an effective
antitumor T-cell response. Cancer immunotherapies to target neoantigens are of growing …

BACKGROUND. Recent genomic and bioinformatic technological advances have made it
possible to dissect the immune response to personalized neoantigens encoded by tumor …